Biodesix, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBiodesix, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings growth of 49% provides fundamental context to the price action. Investors should exercise caution due to high volatility (132% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $12.13 | +23.68% | ABOVE |
| 50 SMA | $14.37 | +4.40% | ABOVE |
| 100 SMA | $11.73 | +27.87% | ABOVE |
| 150 SMA | $10.30 | +45.70% | ABOVE |
| 200 SMA | $9.76 | +53.70% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BDSX in an uptrend right now?
BDSX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BDSX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BDSX overbought or oversold?
BDSX's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is BDSX outperforming the market?
BDSX has a Relative Strength (RS) Rating of 76 out of 99. BDSX is performing about average compared to the market.
Where is BDSX in its 52-week range?
BDSX is trading at $15.00, which is 75% of its 52-week high ($20.11) and 69% above its 52-week low ($3.44).
How volatile is BDSX?
BDSX has a Beta of 0.25 and 52-week volatility of 132%. It's less volatile than the S&P 500 - generally more stable.